Table 4.
Adverse events possibly related to HDM/SCT (Grade >2)
| Toxicity | BD + HDM/SCT (n = 28) | HDM/SCT (n = 28) | P value |
|---|---|---|---|
| Nausea or vomiting |
8 (28.6%) |
10 (35.7%) |
0.78 |
| Diarrhea |
6 (21.4%) |
7 (25%) |
1.0 |
| Mucositis |
5 (17.9%) |
7 (25%) |
0.75 |
| Hepatic |
5 (17.9%) |
5 (17.9%) |
1.0 |
| Renal |
4 (14.3%) |
6 (21.4%) |
0.73 |
| Cardiac |
3 (10.7%) |
6 (21.4%) |
0.47 |
| Febrile neutropenia |
9 (32.1%) |
7 (25%) |
0.77 |
| Sepsis | 0 | 2 (7.1%) | 0.5 |
BD, bortezomib in combination with dexamethasone; HDM/SCT, high dose melphalan and autologous stem cell transplantation.